{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:36:56Z","timestamp":1779255416934,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03002-1","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:04:53Z","timestamp":1766217893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-1718","authenticated-orcid":false,"given":"Morten","family":"Lindhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-6237","authenticated-orcid":false,"given":"Christian Klyver","family":"Tikkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothi","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2528-4359","authenticated-orcid":false,"given":"Juliette","family":"Cattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-279X","authenticated-orcid":false,"given":"Barnaby","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-7784","authenticated-orcid":false,"given":"Samuel J. P.","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-051X","authenticated-orcid":false,"given":"Barrie","family":"Chubb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8595-6187","authenticated-orcid":false,"given":"Tina","family":"Damgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-3578","authenticated-orcid":false,"given":"Rikke","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"3002_CR1","unstructured":"International Diabetes Federation (2025) IDF Diabetes Atlas 11th Edition. Available from https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/. Accessed April 2025"},{"key":"3002_CR2","unstructured":"Diabetes Foreningen. Facts about diabetes in Denmark \u2013 Diabetes [Internet]. Available from https:\/\/diabetes.dk\/diabetesforeningen\/in-english\/facts-about-diabetes-in-denmark.aspx. Accessed April 2025"},{"issue":"3","key":"3002_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15455","volume":"42","author":"EK Fredslund","year":"2025","unstructured":"Fredslund EK, Sandb\u00e6k A, Pr\u00e6torius T. Attributable one-year healthcare cost of incident type 2 diabetes: a population-wide difference-in-differences study in Denmark. Diabet Med. 2025;42(3):e15455. https:\/\/doi.org\/10.1111\/dme.15455.","journal-title":"Diabet Med"},{"issue":"11","key":"3002_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.2337\/dc21-2151","volume":"45","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang P, Shao H, Andes LJ, Imperatore G. Medical costs associated with diabetes complications in Medicare beneficiaries aged 65 years or older with type 2 diabetes. Diabetes Care. 2022;45(11):2570\u20136. https:\/\/doi.org\/10.2337\/dc21-2151.","journal-title":"Diabetes Care"},{"issue":"9","key":"3002_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15326","volume":"41","author":"N Hex","year":"2024","unstructured":"Hex N, MacDonald R, Pocock J, et al. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model. Diabet Med. 2024;41(9):e15326. https:\/\/doi.org\/10.1111\/dme.15326.","journal-title":"Diabet Med"},{"key":"3002_CR6","unstructured":"International Diabetes Federation (2023) IDF Diabetes Atlas Reports: Diabetes and kidney disease. Available from https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-reports\/diabetes-and-kidney-disease\/. Accessed February 2025"},{"issue":"1","key":"3002_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-025-02721-4","volume":"26","author":"M Lindhardt","year":"2025","unstructured":"Lindhardt M, Knudsen ST, Saxild T, Charles M, Borg R. Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study. BMC Prim Care. 2025;26(1):23. https:\/\/doi.org\/10.1186\/s12875-025-02721-4.","journal-title":"BMC Prim Care"},{"issue":"3","key":"3002_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. J Diabetes Investig. 2021;12(3):346\u201356. https:\/\/doi.org\/10.1111\/jdi.13355.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"3002_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138. https:\/\/doi.org\/10.1681\/ASN.2012070718.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3002_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567\u201381. https:\/\/doi.org\/10.1016\/j.kint.2018.04.011.","journal-title":"Kidney Int"},{"key":"3002_CR11","unstructured":"International Diabetes Federation. IDF-ISN Policy Brief. Renewing the fight: a call to action on diabetes and chronic kidney disease. Available from https:\/\/idf.org\/events\/webinars\/renewing-the-fight-a-call-to-action-for-diabetes-and-chronic-kidney-disease\/. Accessed February 2025."},{"issue":"12","key":"3002_CR12","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"5S","key":"3002_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"key":"3002_CR14","unstructured":"Danish Nephrology Society (2024) Guideline for Diabetic Kidney Disease in Type 2 Diabetes. Available from https:\/\/nephrology.dk\/vejledninger\/ckd-mbd\/kronisk-nyresygdom\/diabetisk-nyresygdom-i-t2dm\/. Accessed March 2025"},{"key":"3002_CR15","unstructured":"The Danish Endocrine Society (2024) Treatment guidelines for Type 2 Diabetes. Available from https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/behandling-og-kontrol-af-type-2-diabetes\/#elementor-toc__heading-anchor-14. Accessed July 2025"},{"key":"3002_CR16","unstructured":"Danish Diabetes Association. Available from https:\/\/diabetestal.nu\/search?id=1658. Accessed March 2025"},{"issue":"11","key":"3002_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344. https:\/\/doi.org\/10.1016\/S2213-8587(19)30311-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3002_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367. https:\/\/doi.org\/10.1016\/S2213-8587(19)30066-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3002_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117.","journal-title":"Diabetes Metab"},{"issue":"5","key":"3002_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019;45(5):409\u201318. https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001.","journal-title":"Diabetes Metab"},{"issue":"19","key":"3002_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"9","key":"3002_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041\u201351. https:\/\/doi.org\/10.1093\/ndt\/gfad009.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3002_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"10","key":"3002_CR24","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356. https:\/\/doi.org\/10.1038\/s41591-024-03133-0.","journal-title":"Nat Med"},{"issue":"1","key":"3002_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/13696998.2022.2035132","volume":"25","author":"RF Pollock","year":"2022","unstructured":"Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ. 2022;25(1):393\u2013402. https:\/\/doi.org\/10.1080\/13696998.2022.2035132.","journal-title":"J Med Econ"},{"issue":"9","key":"3002_CR26","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333. https:\/\/doi.org\/10.1007\/s00125-013-2940-y.","journal-title":"Diabetologia"},{"key":"3002_CR27","unstructured":"World Health Organisation (2020) Global Health Observatory data repository: Life tables by country (Denamker). Available from https:\/\/apps.who.int\/gho\/data\/view.main.60450?lang=en. Accessed March 2025"},{"key":"3002_CR28","unstructured":"Danish Ministry of Finance (2024) Guide to socio-economic impact assessments. Available from https:\/\/fm.dk\/media\/4tkj2o4w\/noegletalskatalog-november-2024.pdf. Accessed February 2025"},{"issue":"4","key":"3002_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"22","key":"3002_CR30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"11","key":"3002_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-018-1086-1","volume":"18","author":"A Bilal","year":"2018","unstructured":"Bilal A, Pratley RE. Cardiovascular outcomes trials update: insights from the DEVOTE trial. Curr Diab Rep. 2018;18(11):102. https:\/\/doi.org\/10.1007\/s11892-018-1086-1.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"3002_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1501352.","journal-title":"N Engl J Med"},{"issue":"17","key":"3002_CR33","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716\u201330. https:\/\/doi.org\/10.1056\/NEJMoa075392.","journal-title":"N Engl J Med"},{"issue":"2","key":"3002_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa0808431.","journal-title":"N Engl J Med"},{"issue":"24","key":"3002_CR35","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372. https:\/\/doi.org\/10.1056\/NEJMoa0802987.","journal-title":"N Engl J Med"},{"key":"3002_CR36","unstructured":"Eurostat. Harmonised index of consumer prices (HICP). Available from https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/prc_hicp_aind__custom_13229140\/default\/table?lang=en. Accessed January 2025"},{"issue":"6","key":"3002_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737167.2020.1837626","volume":"20","author":"J Kjellberg","year":"2020","unstructured":"Kjellberg J, Tikkanen CK, Bagger M, G\u00e6de P. Short-term societal economic burden of first-incident type 2 diabetes-related complications - a nationwide cohort study. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):577\u201386. https:\/\/doi.org\/10.1080\/14737167.2020.1837626.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"3002_CR38","volume":"62","author":"LN S\u00f8ndergaard","year":"2015","unstructured":"S\u00f8ndergaard LN, Christensen AB, Vinding AL, Kj\u00e6r IL, Larsen P. Elevated costs and high one-year mortality in patients with diabetic foot ulcers after surgery. Dan Med J. 2015;62(4):A5050.","journal-title":"Dan Med J"},{"issue":"4","key":"3002_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13696998.2016.1269774","volume":"20","author":"N Hoskins","year":"2017","unstructured":"Hoskins N, Tikkanen CK, Pedersen-Bjergaard U. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the local impact of hypoglycemia tool. J Med Econ. 2017;20(4):363\u201370. https:\/\/doi.org\/10.1080\/13696998.2016.1269774.","journal-title":"J Med Econ"},{"key":"3002_CR40","unstructured":"Carlsson KS, Andersson E, Fridhammar A, Willis, M (2015) P\u00e5verkbara kostnader f\u00f6r typ 2-diabetes \u00e5r 2020 och \u00e5r 2030 i Sverige. Prognoser med IHE Cohort Model of Type 2 Diabetes. IHE Report\/IHE Rapport 2015. The Swedish Institute for Health Economics. Available from https:\/\/ihe.se\/app\/uploads\/2017\/10\/IHE-Rapport_2015_1.pdf. Accessed April 2025"},{"key":"3002_CR41","unstructured":"DRG 2024 tariffs in Denmark. Available from https:\/\/sundhedsdatastyrelsen.dk\/data-og-registre\/sundhedsoekonomi\/drg\/drg-takster. Accessed November 2024"},{"issue":"1","key":"3002_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jval.2015.10.010","volume":"19","author":"A Hayes","year":"2016","unstructured":"Hayes A, Arima H, Woodward M, et al. Changes in quality of life associated with complications of diabetes: results from the ADVANCE study. Value Health. 2016;19(1):36\u201341. https:\/\/doi.org\/10.1016\/j.jval.2015.10.010.","journal-title":"Value Health"},{"key":"3002_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.diabres.2016.12.019","volume":"130","author":"AH Briggs","year":"2017","unstructured":"Briggs AH, Bhatt DL, Scirica BM, et al. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: a subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Res Clin Pract. 2017;130:24\u201333. https:\/\/doi.org\/10.1016\/j.diabres.2016.12.019.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"3002_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-019-00775-8","volume":"37","author":"H Shao","year":"2019","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: the health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37(7):921\u20139. https:\/\/doi.org\/10.1007\/s40273-019-00775-8.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"3002_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.910","volume":"14","author":"A Bagust","year":"2005","unstructured":"Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217\u201330. https:\/\/doi.org\/10.1002\/hec.910.","journal-title":"Health Econ"},{"issue":"5","key":"3002_CR46","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","volume":"96","author":"P Mitchell","year":"2012","unstructured":"Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688\u201393. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300726.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3002_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/dom.13547","volume":"21","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Buse JB, Mann JFE, et al. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019;21(3):525\u201332. https:\/\/doi.org\/10.1111\/dom.13547.","journal-title":"Diabetes Obes Metab"},{"key":"3002_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-90","volume":"11","author":"M Evans","year":"2013","unstructured":"Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90. https:\/\/doi.org\/10.1186\/1477-7525-11-90.","journal-title":"Health Qual Life Outcomes"},{"key":"3002_CR49","unstructured":"National Institute for Health and Care Excellence (2010) Final appraisal determination: liraglutide for the treatment of type 2 diabetes mellitus Available from https:\/\/www.nice.org.uk\/guidance\/ta203. Accessed July 2025"},{"issue":"6","key":"3002_CR50","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/dom.12890","volume":"19","author":"B Hunt","year":"2017","unstructured":"Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017;19(6):842\u20139. https:\/\/doi.org\/10.1111\/dom.12890.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3002_CR51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s13300-017-0239-6","volume":"8","author":"P Mezquita-Raya","year":"2017","unstructured":"Mezquita-Raya P, Ram\u00edrez de Arellano A, Kragh N, Vega-Hernandez G, P\u00f6hlmann J, et al. Liraglutide versus lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of type 2 diabetes in Spain. Diabetes Ther. 2017;8(2):401\u201315. https:\/\/doi.org\/10.1007\/s13300-017-0239-6.","journal-title":"Diabetes Ther"},{"key":"3002_CR52","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.clinthera.2017.05.354","volume":"39","author":"B Hunt","year":"2017","unstructured":"Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R. Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: liraglutide versus lixisenatide. Clin Ther. 2017;39:1347\u201359. https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.354.","journal-title":"Clin Ther"},{"issue":"3","key":"3002_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","volume":"7","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7(3):401\u20138. https:\/\/doi.org\/10.2215\/CJN.07650711.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3002_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00059-024-05235-4","volume":"49","author":"S Vondenhoff","year":"2024","unstructured":"Vondenhoff S, Schunk SJ, Noels H. Increased cardiovascular risk in patients with chronic kidney disease. Herz. 2024;49(2):95\u2013104. https:\/\/doi.org\/10.1007\/s00059-024-05235-4.","journal-title":"Herz"},{"issue":"11","key":"3002_CR55","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1464-5491.2005.01657.x","volume":"22","author":"AJ Lee","year":"2005","unstructured":"Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005;22(11):1482\u20136. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01657.x.","journal-title":"Diabet Med"},{"key":"3002_CR56","unstructured":"Svensson R, Shire I, Vitor C, Carlqvist P Cost-effectiveness threshold in Denmark's new health technology assessment process: what do we know so far? Nordic Market Access. HTA131. Available from https:\/\/www.ispor.org\/docs\/default-source\/euro2023\/isporeurope23carlqvisthta131poster131014-pdf.pdf?sfvrsn=1cc9d1f1_0#:~:text=The%20final%20estimated%20cost%2Deffectiveness,using%20the%20new%20assessment%20process. Accessed February 2025"},{"issue":"8","key":"3002_CR57","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0005","volume":"12","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12(8):e230005. https:\/\/doi.org\/10.1530\/EC-23-0005.","journal-title":"Endocr Connect"},{"issue":"11","key":"3002_CR58","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","volume":"16","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Iatridi F, Ferro C, et al. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J. 2023;16(11):1885\u2013907. https:\/\/doi.org\/10.1093\/ckj\/sfad139.","journal-title":"Clin Kidney J"},{"key":"3002_CR59","unstructured":"The Danish Nephrology Society (2024) Guideline for chronic kidney disease. Available from https:\/\/nephrology.dk\/vejledninger\/ckd-mbd\/kronisk-nyresygdom\/. Accessed March 2025]"},{"key":"3002_CR60","unstructured":"Novo Nordisk A\/S (2024) Annual Report 2024. Available from https:\/\/www.novonordisk.com\/content\/dam\/nncorp\/global\/en\/investors\/irmaterial\/annual_report\/2025\/novo-nordisk-annual-report-2024.pdf. Accessed June 2025"},{"key":"3002_CR61","doi-asserted-by":"crossref","unstructured":"Trinh D, McDonald M (2024) Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Environmental Scan. Canadian Agency for Drugs and Technologies in Health Report No.: ES0370.","DOI":"10.51731\/cjht.2024.861"},{"issue":"5","key":"3002_CR62","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"3002_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3949\/ccjm.92a.24113","volume":"92","author":"AE Mehta","year":"2025","unstructured":"Mehta AE, Lomeli LD, Pantalone KM. Glucagon-like peptide-1 receptor agonists and pancreatitis: a reconcilable divorce. Cleve Clin J Med. 2025;92(8):483\u20139.","journal-title":"Cleve Clin J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03002-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:02:25Z","timestamp":1770019345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03002-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3002"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03002-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual patient data is included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PR has served as consultant on advisory boards for Astra Zeneca, Abbott, Bayer, Novartis, Boehringer Ingelheim, Gilead and Sanofi (honoraria to his institution); has received unrestricted grants (to his institution) from Astra Zeneca, Bayer, and Novo Nordisk; and grants from Bayer, Novo Nordisk and Lexicon pharmaceuticals (study medication to investigator initiated study). ML has received speaker and consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and GlaxoSmithKline. RB reports honoraria for education and consultancy from Astra Zeneca, Bayer, Novo Nordisk and Boehringer Ingelheim.\u00a0She is an investigator in clinical studies sponsored by Boehringer Ingelheim, AstraZeneca or Bayer; and has received unrestricted research grants from Boehringer Ingelheim. JM and BC are employees of Novo Nordisk A\/S. CKT and TD are employees of Novo Nordisk Denmark A\/S. JC, BH and SJPM are employees of Ossian Health Economics and Communications. Ossian received consulting fees from Novo Nordisk A\/S to support the preparation of the analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}